Ortin Laboratories Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: September 3, 2024, 11:03 pm

Market Cap	16.4 Cr.
Current Price	20.1
High / Low	26.4/16.2
Stock P/E
Book Value	3.47
Dividend Yield	0.00 %
ROCE	60.2 %
ROE	118 %
Face Value	10.0
PEG Ratio	0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Ortin Laboratories Ltd

Competitors of Ortin Laboratories Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	7.27 Cr.	3.80	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	50.4 Cr.	67.9	94.9/30.8	17.1	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	41.3 Cr.	28.2	29.0/8.74	42.2	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	68.2 Cr.	90.5	155/81.2	11.0	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,162.60 Cr	1,062.34		42.67	185.19	0.37%	16.18%	16.43%	6.27

All Competitor Stocks of Ortin Laboratories Ltd

Quarterly Result

Metric	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Sales	1.76	1.98	2.29	1.66	2.45	2.62	0.79	1.17	1.49	1.57	0.27	0.14	0.30
Expenses	1.55	1.61	2.00	1.65	2.59	2.41	1.01	0.55	1.52	1.39	1.17	2.74	3.35
Operating Profit	0.21	0.37	0.29	0.01	-0.14	0.21	-0.22	0.62	-0.03	0.18	-0.90	-2.60	-3.05
OPM %	11.93%	18.69%	12.66%	0.60%	-5.71%	8.02%	-27.85%	52.99%	-2.01%	11.46%	-333.33%	-1,857.14%	-1,016.67%
Other Income	0.05	0.00	0.04	0.00	0.00	0.00	0.00	0.00	-0.03	0.00	0.00	0.00	0.00
Interest	0.19	0.18	0.19	0.19	0.24	0.10	0.09	0.10	0.12	0.11	0.15	0.14	0.08
Depreciation	0.07	0.07	0.07	-0.07	0.23	0.07	0.07	0.07	0.03	0.06	0.06	0.06	0.05
Profit before tax	0.00	0.12	0.07	-0.11	-0.61	0.04	-0.38	0.45	-0.21	0.01	-1.11	-2.80	-3.18
Tax %		25.00%	28.57%	-18.18%	-24.59%	1,150.00%	-121.05%	0.00%	-4.76%	0.00%	1.80%	-0.71%	30.19%
Net Profit	0.80	0.09	0.05	-0.09	-0.45	-0.43	0.08	0.46	-0.20	0.02	-1.12	-2.79	-4.14
EPS in Rs	0.98	0.11	0.06	-0.11	-0.55	-0.53	0.10	0.57	-0.25	0.02	-1.38	-3.43	-5.09

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Sales	74.74	67.00	60.29	62.72	61.57	79.63	167.51	197.36	8.16	8.23	6.00	2.28
Expenses	68.17	60.90	53.80	56.83	56.12	74.22	160.83	191.66	6.92	7.85	5.47	8.65
Operating Profit	6.57	6.10	6.49	5.89	5.45	5.41	6.68	5.70	1.24	0.38	0.53	-6.37
OPM %	8.79%	9.10%	10.76%	9.39%	8.85%	6.79%	3.99%	2.89%	15.20%	4.62%	8.83%	-279.39%
Other Income	0.24	0.81	0.00	0.57	0.32	0.45	0.13	0.18	0.05	0.19	0.01	0.00
Interest	3.55	3.72	3.52	3.42	2.94	3.49	3.22	3.21	0.87	0.81	0.40	0.48
Depreciation	1.40	1.51	1.64	1.65	1.70	1.69	1.75	1.96	0.29	0.29	0.25	0.23
Profit before tax	1.86	1.68	1.33	1.39	1.13	0.68	1.84	0.71	0.13	-0.53	-0.11	-7.08
Tax %	41.40%	29.17%	32.33%	41.01%	55.75%	0.00%	30.43%	181.69%	-623.08%	-24.53%	-18.18%	13.56%
Net Profit	1.09	1.19	0.90	0.83	0.50	0.68	1.28	-0.56	0.95	-0.40	-0.09	-8.04
EPS in Rs	0.64	0.70	0.53	0.49	0.30	0.40	0.76	-0.33	1.17	-0.49	-0.11	-9.89
Dividend Payout %	38.85%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	9.17%	-24.37%	-7.78%	-39.76%	36.00%	88.24%	-143.75%	269.64%	-142.11%	77.50%	-8833.33%
Change in YoY Net Profit Growth (%)	0.00%	-33.54%	16.59%	-31.98%	75.76%	52.24%	-231.99%	413.39%	-411.75%	219.61%	-8910.83%

Ortin Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: Unknown

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	16.94	16.94	16.94	16.94	16.94	16.94	16.94	16.94	8.13	8.13	8.13	8.13
Reserves	3.84	5.02	5.50	6.33	6.46	7.14	8.15	6.88	3.22	2.83	2.73	-5.31
Borrowings	17.92	18.68	20.96	20.85	17.34	17.34	19.47	19.57	6.94	6.14	6.45	1.80
Other Liabilities	34.80	31.93	23.87	21.22	20.79	32.24	60.53	73.13	2.97	3.61	3.89	1.97
Total Liabilities	73.50	72.57	67.27	65.34	61.53	73.66	105.09	116.52	21.26	20.71	21.20	6.59
Fixed Assets	24.77	23.90	21.83	21.63	20.69	20.03	21.29	22.45	14.38	14.21	13.96	0.01
CWIP	0.00	0.00	0.00	0.00	0.35	0.40	0.53	0.43	0.43	0.43	0.43	0.00
Investments	0.03	0.03	0.03	0.03	0.07	0.08	0.08	0.07	0.00	0.00	0.00	0.00
Other Assets	48.70	48.64	45.41	43.68	40.42	53.15	83.19	93.57	6.45	6.07	6.81	6.58
Total Assets	73.50	72.57	67.27	65.34	61.53	73.66	105.09	116.52	21.26	20.71	21.20	6.59

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-11.35	-12.58	-14.47	-14.96	-11.89	-11.93	-12.79	-13.87	-5.70	-5.76	-5.92	-8.17

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	134.10	116.69	103.77	53.13	90.35	100.15	82.43	68.71	174.90	143.69	208.05	283.36
Inventory Days	102.80	162.92	192.30	148.72	158.21	152.21	100.07	117.80	169.10	136.29	279.94	4.92
Days Payable	199.45	197.95	151.09	24.82	108.10	143.09	145.12	155.80	123.82	61.88	166.89	7.87
Cash Conversion Cycle	37.45	81.66	144.97	177.04	140.45	109.28	37.38	30.70	220.17	218.10	321.10	280.40
Working Capital Days	56.94	86.07	118.60	104.81	126.92	108.68	48.94	38.38	158.79	86.93	168.51	313.77
ROCE %	14.90%	13.08%	12.07%	10.92%	9.57%	9.44%	11.77%	8.94%	3.24%	1.58%	1.80%	-60.19%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	15.68%	15.68%	15.68%	15.68%	15.68%	15.68%	21.51%	7.36%	7.37%	7.36%	1.23%	1.23%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.25%
Public	84.32%	84.32%	84.32%	84.32%	84.32%	84.31%	78.49%	92.63%	92.64%	92.64%	98.76%	92.53%
No. of Shareholders	11,947	12,819	12,662	12,571	12,449	12,781	12,585	12,181	11,836	12,314	12,192	11,952

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 12
FaceValue	10.00
Basic EPS (Rs.)	2.73
Diluted EPS (Rs.)	2.73
Cash EPS (Rs.)	3.59
Book Value[Excl.RevalReserv]/Share (Rs.)	14.47
Book Value[Incl.RevalReserv]/Share (Rs.)	14.47
Revenue From Operations / Share (Rs.)	50.63
PBDIT / Share (Rs.)	6.99
PBIT / Share (Rs.)	6.13
PBT / Share (Rs.)	4.20
Net Profit / Share (Rs.)	2.73
NP After MI And SOA / Share (Rs.)	2.73
PBDIT Margin (%)	13.81
PBIT Margin (%)	12.10
PBT Margin (%)	8.30
Net Profit Margin (%)	5.38
NP After MI And SOA Margin (%)	5.38
Return on Networth / Equity (%)	18.85
Return on Capital Employeed (%)	34.77
Return On Assets (%)	5.67
Long Term Debt / Equity (X)	0.11
Total Debt / Equity (X)	0.58
Current Ratio (X)	1.11
Quick Ratio (X)	0.82
Interest Coverage Ratio (X)	3.63
Interest Coverage Ratio (Post Tax) (X)	2.42
Enterprise Value (Cr.)	62.39
EV / Net Operating Revenue (X)	0.72
EV / EBITDA (X)	5.27
MarketCap / Net Operating Revenue (X)	0.56
Price / BV (X)	1.97
Price / Net Operating Revenue (X)	0.56
EarningsYield	0.09

After reviewing the key financial ratios for Ortin Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 12, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
For Basic EPS (Rs.), as of Mar 12, the value is 2.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Diluted EPS (Rs.), as of Mar 12, the value is 2.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Cash EPS (Rs.), as of Mar 12, the value is 3.59. This value is within the healthy range. No previous period data is available for comparison.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 12, the value is 14.47. No previous period data is available for comparison.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 12, the value is 14.47. No previous period data is available for comparison.
For Revenue From Operations / Share (Rs.), as of Mar 12, the value is 50.63. No previous period data is available for comparison.
For PBDIT / Share (Rs.), as of Mar 12, the value is 6.99. This value is within the healthy range. No previous period data is available for comparison.
For PBIT / Share (Rs.), as of Mar 12, the value is 6.13. This value is within the healthy range. No previous period data is available for comparison.
For PBT / Share (Rs.), as of Mar 12, the value is 4.20. This value is within the healthy range. No previous period data is available for comparison.
For Net Profit / Share (Rs.), as of Mar 12, the value is 2.73. This value is within the healthy range. No previous period data is available for comparison.
For NP After MI And SOA / Share (Rs.), as of Mar 12, the value is 2.73. This value is within the healthy range. No previous period data is available for comparison.
For PBDIT Margin (%), as of Mar 12, the value is 13.81. This value is within the healthy range. No previous period data is available for comparison.
For PBIT Margin (%), as of Mar 12, the value is 12.10. This value is within the healthy range. No previous period data is available for comparison.
For PBT Margin (%), as of Mar 12, the value is 8.30. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For Net Profit Margin (%), as of Mar 12, the value is 5.38. This value is within the healthy range. No previous period data is available for comparison.
For NP After MI And SOA Margin (%), as of Mar 12, the value is 5.38. This value is below the healthy minimum of 8. No previous period data is available for comparison.
For Return on Networth / Equity (%), as of Mar 12, the value is 18.85. This value is within the healthy range. No previous period data is available for comparison.
For Return on Capital Employeed (%), as of Mar 12, the value is 34.77. This value is within the healthy range. No previous period data is available for comparison.
For Return On Assets (%), as of Mar 12, the value is 5.67. This value is within the healthy range. No previous period data is available for comparison.
For Long Term Debt / Equity (X), as of Mar 12, the value is 0.11. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
For Total Debt / Equity (X), as of Mar 12, the value is 0.58. This value is within the healthy range. No previous period data is available for comparison.
For Current Ratio (X), as of Mar 12, the value is 1.11. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
For Quick Ratio (X), as of Mar 12, the value is 0.82. This value is below the healthy minimum of 1. No previous period data is available for comparison.
For Interest Coverage Ratio (X), as of Mar 12, the value is 3.63. This value is within the healthy range. No previous period data is available for comparison.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 12, the value is 2.42. This value is below the healthy minimum of 3. No previous period data is available for comparison.
For Enterprise Value (Cr.), as of Mar 12, the value is 62.39. No previous period data is available for comparison.
For EV / Net Operating Revenue (X), as of Mar 12, the value is 0.72. This value is below the healthy minimum of 1. No previous period data is available for comparison.
For EV / EBITDA (X), as of Mar 12, the value is 5.27. This value is within the healthy range. No previous period data is available for comparison.
For MarketCap / Net Operating Revenue (X), as of Mar 12, the value is 0.56. This value is below the healthy minimum of 1. No previous period data is available for comparison.
For Price / BV (X), as of Mar 12, the value is 1.97. This value is within the healthy range. No previous period data is available for comparison.
For Price / Net Operating Revenue (X), as of Mar 12, the value is 0.56. This value is below the healthy minimum of 1. No previous period data is available for comparison.
For EarningsYield, as of Mar 12, the value is 0.09. This value is below the healthy minimum of 5. No previous period data is available for comparison.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation. If you have any questions or need more detailed insights, please feel free to reach out.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Ortin Laboratories Ltd as of February 24, 2025 is: ₹50.12

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 24, 2025, Ortin Laboratories Ltd is Undervalued by 149.35% compared to the current share price ₹20.10

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Ortin Laboratories Ltd as of February 24, 2025 is: 31.28

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 24, 2025, Ortin Laboratories Ltd is Undervalued by 55.62% compared to the current share price ₹20.10

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -37.59%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has shown consistent growth in sales (66.29 cr) and profit (0.25 cr) over the years.	The stock has a low average ROCE of 3.09%, which may not be favorable. The stock has a high average Working Capital Days of 118.11, which may not be favorable. The stock has a high average Cash Conversion Cycle of 149.89, which may not be favorable. The company has higher borrowings (14.46) compared to reserves (4.40), which may suggest financial risk.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ortin Laboratories Ltd:
1. Net Profit Margin: 5.38%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 34.77% (Industry Average ROCE: 16.18%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 18.85% (Industry Average ROE: 16.43%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 2.42
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.82
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 0 (Industry average Stock P/E: 42.67)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.58
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

No data availabale for About the Company

INDUSTRY	ADDRESS	CONTACT
Industry not found	Address not found	Contact not found

Management Data not Available

FAQ

What is the latest intrinsic value of Ortin Laboratories Ltd?

The latest intrinsic value of Ortin Laboratories Ltd as on 04 February 2025 is ₹50.12, which is 149.35% higher than the current market price of ₹20.10, indicating the stock is undervalued by 149.35%. The stock has a market capitalization of 16.4 Cr. and recorded a high/low of 26.4/16.2 during the current fiscal year 2024-2025. As of Mar 2024, the company has reserves of ₹-5.31 Cr and total liabilities of 6.59 Cr.

What is the Market Cap of Ortin Laboratories Ltd?

The Market Cap of Ortin Laboratories Ltd is 16.4 Cr..

What is the current Stock Price of Ortin Laboratories Ltd as on 04 February 2025?

The current stock price of Ortin Laboratories Ltd as on 04 February 2025 is 20.1.

What is the High / Low of Ortin Laboratories Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Ortin Laboratories Ltd stocks is 26.4/16.2.

What is the Stock P/E of Ortin Laboratories Ltd?

The Stock P/E of Ortin Laboratories Ltd is .

What is the Book Value of Ortin Laboratories Ltd?

The Book Value of Ortin Laboratories Ltd is 3.47.

What is the Dividend Yield of Ortin Laboratories Ltd?

The Dividend Yield of Ortin Laboratories Ltd is 0.00 %.

What is the ROCE of Ortin Laboratories Ltd?

The ROCE of Ortin Laboratories Ltd is 60.2 %.

What is the ROE of Ortin Laboratories Ltd?

The ROE of Ortin Laboratories Ltd is 118 %.

What is the Face Value of Ortin Laboratories Ltd?

The Face Value of Ortin Laboratories Ltd is 10.0.